• The filing application is based on improvements seen across key efficacy endpoints from the global Phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision) in active TED
  • Enspryng (satralizumab) has the potential to become the first at-home subcutaneous disease-modifying standard of care for TED
  • TED is an autoimmune disease affecting approximately 155 out of every 100,000 people that can lead to facial disfigurement and vision-threatening complications if left untreated